kesäkuu 2021

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

Pemigatinib – a oral FGFR1-3 inhibitor has shown efficacy and safety in patients with advanced/metastatic cholangiocarcinoma publish in the Lancet Oncol 2020. In this MEDtalk Abou-Alfa K. Ghassan present the update FIGHT-202 study, where overall survival for responders was more than twice as long vs for non-responders

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Rekisteröidy
Onko sinulla jo profiili Kirjaudu sisään

Back to top

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Aina käytössä

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non Necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Kesto	Kuvaus
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors.
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.

Preferences

Preference cookies are used to store user preferences to provide content that is customized and convenient for the users, like the language of the website or the location of the visitor.

Cookie	Kesto	Kuvaus
_gat_UA-43794127-5	1 minute	This is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

Avaa artikkeli

Asiaan liittyvä sisältö

Relatlimab + nivolumab: a potential new combination in first-line advanced melanoma

First-line treatment with relatinib + nivolumab ﻿﻿demonstrated significant PFS benefit﻿﻿ in patients with ﻿advanced melanoma.

Significantly improved pathological complete response with nivolumab + chemotherapy in ﻿NSCLC

First-line treatment with relatinib + nivolumab demonstrated significant PFS benefit in patients with advanced melanoma.

Significantly improved pathological complete response with nivolumab + chemotherapy in NSCLC